Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes—presented at ADA 2026

Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026

PR Newswire

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 5, 2026

View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisks-investigational-zenagamtide-shows-significant-a1c-reductions-with-up-to-14-6-weight-loss-in-adults-with-type-2-diabetespresented-at-ada-2026--302793124.htmlSOURCE NOVO NORDISK INC.

The articles, information, and content displayed on this webpage may